DOCSLIB.ORG

Standards of Medical Care in Diabetes—2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Standards of Medical Care in Diabetes—2017 THE JOURNAL OF CLINICAL AND APPLIED RESEARCH AND EDUCATION VOLUME 40 | SUPPLEMENT 1 WWW.DIABETES.ORG/DIABETESCARE JANUARY 2017 PLE M E P N U T S 1 AMERICAN DIABETES ASSOCIATION STANDARDS OF MEDICAL CARE IN DIABETES—2017 ISSN 0149-5992 American Diabetes Association Standards of Medical Care in Diabetesd2017 January 2017 Volume 40, Supplement 1 [T]he simple word Care may suffice to express [the journal’s] philosophical mission. The new journal is designed to promote better patient care by serving the expanded needs of all health professionals committed to the care of patients with diabetes. As such, the American Diabetes Association views Diabetes Care as a reaffirmation of Francis Weld Peabody’s contention that “the secret of the care of the patient is in caring for the patient.” —Norbert Freinkel, Diabetes Care, January-February 1978 EDITOR IN CHIEF William T. Cefalu, MD ASSOCIATE EDITORS EDITORIAL BOARD George Bakris, MD Nicola Abate, MD Maureen Monaghan, PhD, CDE Lawrence Blonde, MD, FACP Vanita R. Aroda, MD Kristen J. Nadeau, MD, MS Andrew J.M. Boulton, MD Geremia Bolli, MD Kwame Osei, MD David D’Alessio, MD John B. Buse, MD, PhD Kevin A. Peterson, MD, MPH, FRCS(Ed), Mary de Groot, PhD Robert J. Chilton, DO, FACC, FAHA FAAFP Eddie L. Greene, MD Kenneth Cusi, MD, FACP, FACE Jonathan Q. Purnell, MD Frank B. Hu, MD, MPH, PhD Paresh Dandona, MD, PhD Peter Reaven, MD Steven E. Kahn, MB, ChB J. Hans DeVries, MD, PhD Ravi Retnakaran, MD, MSc, FRCPC Derek LeRoith, MD, PhD Ele Ferrannini, MD Helena Wachslicht Rodbard, MD Robert G. Moses, MD Franco Folli, MD, PhD Elizabeth Seaquist, MD Stephen Rich, PhD Meredith A. Hawkins, MD, MS Guntram Schernthaner, MD Matthew C. Riddle, MD Richard Hellman, MD David J. Schneider, MD Julio Rosenstock, MD Norbett Hermanns, PhD, MSc Norbert Stefan, MD William V. Tamborlane, MD George S. Jeha, MD Jan S. Ulbrecht, MB, BS Katie Weinger, EdD, RN Irl B. Hirsch, MD, MACP Joseph Wolfsdorf, MD, BCh Judith Wylie-Rosett, EdD, RD Lee M. Kaplan, MD, PhD Tien Yin Wong, MBBS, FRCSE, FRANZCO, M. Sue Kirkman, MD MPH, PhD Ildiko Lingvay, MD, MPH, MSCS Bernard Zinman, CM, MD, FRCPC, FACP Harold David McIntyre, MD, FRACP AMERICAN DIABETES ASSOCIATION OFFICERS CHAIR OF THE BOARD David A. DeMarco, PhD PRESIDENT, MEDICINE & SCIENCE Alvin C. Powers, MD PRESIDENT, HEALTH CARE & EDUCATION Brenda Montgomery, RN, MSHS, CDE SECRETARY/TREASURER Umesh Verma CHIEF EXECUTIVE OFFICER Kevin L. Hagan The mission of the American Diabetes Association is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. Diabetes Care is a journal for the health care practitioner that is intended to increase knowledge, stimulate research, and promote better management of people with diabetes. To achieve these goals, the journal publishes original research on human studies in the following categories: Clinical Care/Education/Nutrition/ Psychosocial Research, Epidemiology/Health Services Research, Emerging Technologies and Therapeutics, Pathophysiology/Complications, and Cardiovascular and Metabolic Risk. The journal also publishes ADA statements, consensus reports, clinically relevant review articles, letters to the editor, and health/medical news or points of view. Topics covered are of interest to clinically oriented physicians, researchers, epidemiologists, psychologists, diabetes educators, and other health professionals. More information about the journal can be found online at care.diabetesjournals.org. Copyright © 2017 by the American Diabetes Association, Inc. All rights reserved. Printed in the USA. Requests for permission to reuse content should be sent to Copyright Clearance Center at www.copyright.com or 222 Rosewood Dr., Danvers, MA 01923; phone: (978) 750-8400; fax: (978) 646-8600. Requests for permission to translate should be sent to Permissions Editor, American Diabetes Association, at [email protected]. The American Diabetes Association reserves the right to reject any advertisement for any reason, which need not be disclosed to the party submitting the advertisement. Commercial reprint orders should be directed to Sheridan Content Services, (800) 635-7181, ext. 8065. Single issues of Diabetes Care can be ordered by calling toll-free (800) 232-3472, 8:30 A.M. to 5:00 P.M. EST, Monday through Friday. Outside the United States, call (703) 549-1500. Rates: $75 in the United States, $95 in Canada and Mexico, and $125 for all other countries. Diabetes Care is available online at care.diabetesjournals.org. Please call the numbers listed above, e-mail [email protected], or visit the online journal for more information about submitting manuscripts, publication charges, ordering reprints, PRINT ISSN 0149-5992 subscribing to the journal, becoming an ADA member, advertising, permission to reuse ’ ONLINE ISSN 1935-5548 content, and the journal s publication policies. PRINTED IN THE USA Periodicals postage paid at Alexandria, VA, and additional mailing offices. AMERICAN DIABETES ASSOCIATION PERSONNEL AND CONTACTS VICE PRESIDENT, PUBLISHER EDITORIAL CONTENT MANAGER ADVERTISING SALES Michael Eisenstein Nancy C. Baldino ASSOCIATE PUBLISHER, PHARMACEUTICAL/DEVICE DIGITAL ADVERTISING SCHOLARLY JOURNALS TECHNICAL EDITORS e-Healthcare Solutions Christian S. Kohler Oedipa Rice John Burke Theresa Cooper Chief Revenue Officer EDITORIAL OFFICE DIRECTOR [email protected] Lyn Reynolds ASSOCIATE DIRECTOR, BILLING & COLLECTIONS (609) 882-8887, ext. 149 PEER REVIEW MANAGER Laurie Ann Hall Shannon Potts PHARMACEUTICAL/DEVICE PRINT ADVERTISING DIRECTOR, MEMBERSHIP/SUBSCRIPTION The Jackson-Gaeta Group, Inc. EDITORIAL ASSISTANT SERVICES B. Joseph Jackson Joan Garrett Donald Crowl [email protected] DIRECTOR, SCHOLARLY JOURNALS Paul Nalbandian SENIOR ADVERTISING MANAGER Heather Norton Blackburn [email protected] Julie DeVoss Graff Tina Auletta CONTENT PRODUCTION MANAGER [email protected] [email protected] Kelly Newton (703) 299-5511 (973) 403-7677 January 2017 Volume 40, Supplement 1 Standards of Medical Care in Diabetes—2017 S1 Introduction S75 9. Cardiovascular Disease and Risk S3 Professional Practice Committee Management S4 Standards of Medical Care in Diabetes—2017: Hypertension/Blood Pressure Control Summary of Revisions Lipid Management S6 1. Promoting Health and Reducing Disparities in Antiplatelet Agents Populations Coronary Heart Disease Diabetes and Population Health S88 10. Microvascular Complications and Tailoring Treatment to Reduce Disparities Foot Care S11 2. Classification and Diagnosis of Diabetes Diabetic Kidney Disease Diabetic Retinopathy Classification Neuropathy Diagnostic Tests for Diabetes Foot Care Categories of Increased Risk for Diabetes (Prediabetes) Type 1 Diabetes S99 11. Older Adults Type 2 Diabetes Gestational Diabetes Mellitus Neurocognitive Function Monogenic Diabetes Syndromes Hypoglycemia Cystic Fibrosis–Related Diabetes Treatment Goals Posttransplantation Diabetes Mellitus Pharmacologic Therapy Treatment in Skilled Nursing Facilities S25 3. Comprehensive Medical Evaluation and and Nursing Homes Assessment of Comorbidities End-of-Life Care Patient-Centered Collaborative Care S105 12. Children and Adolescents Comprehensive Medical Evaluation Assessment of Comorbidities Type 1 Diabetes Type 2 Diabetes S33 4. Lifestyle Management Transition From Pediatric to Adult Care Diabetes Self-management Education and Support Nutrition Therapy S114 13. Management of Diabetes in Pregnancy Physical Activity Diabetes in Pregnancy Smoking Cessation: Tobacco and e-Cigarettes Preconception Counseling Psychosocial Issues Glycemic Targets in Pregnancy Management of Gestational Diabetes Mellitus S44 5. Prevention or Delay of Type 2 Diabetes Management of Preexisting Type 1 Diabetes Lifestyle Interventions and Type 2 Diabetes in Pregnancy Pharmacologic Interventions Postpartum Care Prevention of Cardiovascular Disease Pregnancy and Drug Considerations Diabetes Self-management Education and Support S120 14. Diabetes Care in the Hospital S48 6. Glycemic Targets Hospital Care Delivery Standards Assessment of Glycemic Control Glycemic Targets in Hospitalized Patients A1C Testing Bedside Blood Glucose Monitoring A1C Goals Antihyperglycemic Agents in Hospitalized Hypoglycemia Patients Intercurrent Illness Hypoglycemia S57 7. Obesity Management for the Treatment of Type 2 Medical Nutrition Therapy in the Hospital Diabetes Self-management in the Hospital Standards for Special Situations Assessment Transition From the Acute Care Setting Diet, Physical Activity, and Behavioral Therapy Preventing Admissions and Readmissions Pharmacotherapy Metabolic Surgery S128 15. Diabetes Advocacy S64 8. Pharmacologic Approaches to Glycemic Advocacy Position Statements Treatment S130 Professional Practice Committee Disclosures Pharmacologic Therapy for Type 1 Diabetes Pharmacologic Therapy for Type 2 Diabetes S132 Index This issue is freely accessible online at care.diabetesjournals.org. Keep up with the latest information for Diabetes Care and other ADA titles via Facebook (/ADAJournals) and Twitter (@ADA_Journals). Diabetes Care Volume 40, Supplement 1, January 2017 S1 INTRODUCTION Introduction Diabetes Care 2017;40(Suppl. 1):S1–S2 | DOI: 10.2337/dc17-S001 Diabetes is a complex, chronic illness re- ADA’s clinical practice recommendations Consensus Report quiring continuous medical care with are viewed as important resources for A consensus report contains a compre- multifactorial risk-reduction strategies health care professionals who care for hensive examination by an expert panel beyond glycemic
Load more

Recommended publications
  • Sorbonne Université/China Scholarship Council Program 2021
    Sorbonne Université/China Scholarship Council program 2021 Thesis proposal Title of the research project: Hnf1b regulation during kidney development and regeneration Joint supervision: no Joint PhD (cotutelle): no Thesis supervisor: … Muriel Umbhauer. Email address of the thesis supervisor: [email protected] Institution: …… Sorbonne Université …. Doctoral school (N°+name): ED …. …… ED 515 Complexité du Vivant Research laboratory: UMR7622 CNRS Laboratory of developmental biology Name of the laboratory director: … Sylvie Schneider-Maunoury Email address of the laboratory director: [email protected] Subject description (2 pages max): 1) Study context The POU homeodomain transcription factor hepatocyte nuclear factor 1β (Hnf1b) plays an essential role in vertebrate kidney development. Heterozygous mutations in human HNF1B cause the complex multisystem syndrome known as Renal Cysts And Diabetes (RCAD). The most prominent clinical features of this autosomal dominant disorder are non-diabetic renal disease resulting from abnormal renal development and diabetes mellitus (reviewed by Clissold RL et al., 2015). During early mouse kidney development, Hnf1b has been shown to be required for ureteric bud branching and initiation of nephrogenesis (Lokmane et al., 2010). Hnf1b conditional inactivation in murine nephron progenitors has revealed an additional role in segment fate Xenopus is a well established and attractive model to study kidney development (Krneta-Stankic V. et al, 2017). Renal function at larval stages relies on two pronephroi located on both sides of the body, each consisting on one giant nephron displaying the same structural and functional organisation than the mammalian nephron. Moreover, pronephric and metanephric differentiation and morphogenesis share most of the signalling cascades and gene regulatory networks.
    [Show full text]
  • Overlap of Vitamin a and Vitamin D Target Genes with CAKUT- Related Processes [Version 1; Peer Review: 1 Approved with Reservations]
    F1000Research 2021, 10:395 Last updated: 21 JUL 2021 BRIEF REPORT Overlap of vitamin A and vitamin D target genes with CAKUT- related processes [version 1; peer review: 1 approved with reservations] Ozan Ozisik1, Friederike Ehrhart 2,3, Chris T Evelo 2, Alberto Mantovani4, Anaı̈s Baudot 1,5 1Aix Marseille University, Inserm, MMG, Marseille, 13385, France 2Department of Bioinformatics - BiGCaT, Maastricht University, Maastricht, 6200 MD, The Netherlands 3Department of Bioinformatics, NUTRIM/MHeNs, Maastricht University, Maastricht, 6200 MD, The Netherlands 4Istituto Superiore di Sanità, Rome, 00161, Italy 5Barcelona Supercomputing Center (BSC), Barcelona, 08034, Spain v1 First published: 18 May 2021, 10:395 Open Peer Review https://doi.org/10.12688/f1000research.51018.1 Latest published: 18 May 2021, 10:395 https://doi.org/10.12688/f1000research.51018.1 Reviewer Status Invited Reviewers Abstract Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) are a 1 group of abnormalities affecting the kidneys and their outflow tracts, which include the ureters, the bladder, and the urethra. CAKUT version 1 patients display a large clinical variability as well as a complex 18 May 2021 report aetiology, as only 5% to 20% of the cases have a monogenic origin. It is thereby suspected that interactions of both genetic and 1. Elena Menegola, Università degli Studi di environmental factors contribute to the disease. Vitamins are among the environmental factors that are considered for CAKUT aetiology. In Milano, Milan, Italy this study, we collected vitamin A and vitamin D target genes and Any reports and responses or comments on the computed their overlap with CAKUT-related gene sets.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Using Intervention Mapping to Develop a Digital Self-Management Program for People with Type 2 Diabetes: Tutorial on Mydesmond
    JOURNAL OF MEDICAL INTERNET RESEARCH Hadjiconstantinou et al Tutorial Using Intervention Mapping to Develop a Digital Self-Management Program for People With Type 2 Diabetes: Tutorial on MyDESMOND Michelle Hadjiconstantinou1, BSc, MSc, PhD, CPsychol; Sally Schreder2, MSc; Christopher Brough2, BSc; Alison Northern2; Bernie Stribling2, MBA; Kamlesh Khunti1, MBChB, PhD, MD, FRCGP, DCH, DRCOG; Melanie J Davies1, MB, ChB, MD, FRCP, FRCGP 1Diabetes Research Centre, University of Leicester, Leicester, United Kingdom 2Leicester Diabetes Centre, NHS Trust, University Hospitals of Leicester, Leicester, United Kingdom Corresponding Author: Sally Schreder, MSc Leicester Diabetes Centre NHS Trust University Hospitals of Leicester Gwendolen Road Leicester United Kingdom Phone: 44 116 258 4320 Email: [email protected] Abstract Digital health interventions (DHIs) are increasingly becoming integrated into diabetes self-management to improve behavior. Despite DHIs becoming available to people with chronic conditions, the development strategies and processes undertaken are often not well described. With theoretical frameworks available in current literature, it is vital that DHIs follow a shared language and communicate a robust development process in a comprehensive way. This paper aims to bring a unique perspective to digital development, as it describes the systematic process of developing a digital self-management program for people with type 2 diabetes, MyDESMOND. We provide a step-by-step guide, based on the intervention mapping (IM) framework
    [Show full text]
  • The Prediction of Clinical Outcome Using Hba1c in Acute Ischemic
    Original Article Ann Rehabil Med 2015;39(6):1011-1017 pISSN: 2234-0645 • eISSN: 2234-0653 http://dx.doi.org/10.5535/arm.2015.39.6.1011 Annals of Rehabilitation Medicine The Prediction of Clinical Outcome Using HbA1c in Acute Ischemic Stroke of the Deep Branch of Middle Cerebral Artery Sung Bong Shin, MD1, Tae Uk Kim, MD, PhD1, Jung Keun Hyun, MD, PhD1,2,3, Jung Yoon Kim, MD, PhD1,4 1Department of Rehabilitation Medicine, Dankook University College of Medicine, Cheonan; 2Department of Nanobiomedical Science & WCU Research Center, Dankook University, Cheonan; 3Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan; 4Ewha Brain Institute, Ewha Womans University, Seoul, Korea Objective To elucidate the association between glycemic control status and clinical outcomes in patients with acute ischemic stroke limited to the deep branch of the middle cerebral artery (MCA). Methods We evaluated 65 subjects with first-ever ischemic stroke of the deep branches of the MCA, which was confirmed by magnetic resonance angiography. All subjects had blood hemoglobin A1c (HbA1c) measured at admission. They were classified into two groups according to the level of HbA1c (low <7.0% or high ≥7.0%). Neurological impairment and functional status were evaluated using the National Institutes of Health Stroke Scale (NIHSS), Functional Independence Measure (FIM), Korean version of Modified Barthel Index (K-MBI), Korean version of Mini-Mental State Examination (MMSE-K), and the Loewenstein Occupational Therapy Cognitive Assessment (LOTCA) at admission and discharge. Body mass index, serum glucose, homocysteine and cholesterol levels were also measured at admission. Results The two groups did not show any difference in the NIHSS, FIM, K-MBI, MMSE-K, and LOTCA scores at any time point.
    [Show full text]
  • Supplemental Materials ZNF281 Enhances Cardiac Reprogramming
    Supplemental Materials ZNF281 enhances cardiac reprogramming by modulating cardiac and inflammatory gene expression Huanyu Zhou, Maria Gabriela Morales, Hisayuki Hashimoto, Matthew E. Dickson, Kunhua Song, Wenduo Ye, Min S. Kim, Hanspeter Niederstrasser, Zhaoning Wang, Beibei Chen, Bruce A. Posner, Rhonda Bassel-Duby and Eric N. Olson Supplemental Table 1; related to Figure 1. Supplemental Table 2; related to Figure 1. Supplemental Table 3; related to the “quantitative mRNA measurement” in Materials and Methods section. Supplemental Table 4; related to the “ChIP-seq, gene ontology and pathway analysis” and “RNA-seq” and gene ontology analysis” in Materials and Methods section. Supplemental Figure S1; related to Figure 1. Supplemental Figure S2; related to Figure 2. Supplemental Figure S3; related to Figure 3. Supplemental Figure S4; related to Figure 4. Supplemental Figure S5; related to Figure 6. Supplemental Table S1. Genes included in human retroviral ORF cDNA library. Gene Gene Gene Gene Gene Gene Gene Gene Symbol Symbol Symbol Symbol Symbol Symbol Symbol Symbol AATF BMP8A CEBPE CTNNB1 ESR2 GDF3 HOXA5 IL17D ADIPOQ BRPF1 CEBPG CUX1 ESRRA GDF6 HOXA6 IL17F ADNP BRPF3 CERS1 CX3CL1 ETS1 GIN1 HOXA7 IL18 AEBP1 BUD31 CERS2 CXCL10 ETS2 GLIS3 HOXB1 IL19 AFF4 C17ORF77 CERS4 CXCL11 ETV3 GMEB1 HOXB13 IL1A AHR C1QTNF4 CFL2 CXCL12 ETV7 GPBP1 HOXB5 IL1B AIMP1 C21ORF66 CHIA CXCL13 FAM3B GPER HOXB6 IL1F3 ALS2CR8 CBFA2T2 CIR1 CXCL14 FAM3D GPI HOXB7 IL1F5 ALX1 CBFA2T3 CITED1 CXCL16 FASLG GREM1 HOXB9 IL1F6 ARGFX CBFB CITED2 CXCL3 FBLN1 GREM2 HOXC4 IL1F7
    [Show full text]
  • Management of Hyperglycaemia and Steroid (Glucocorticoid) Therapy
    Management of Hyperglycaemia and Steroid (Glucocorticoid) Therapy October 2014 This document is coded JBDS 08 in the series of JBDS documents Other JBDS documents: Admissions avoidance and diabetes: guidance for clinical commissioning groups and clinical team; December 2013, JBDS 07 The management of the hyperosmolar hyperglycaemic state (HHS) in adults with diabetes; August 2012, JBDS 06 Glycaemic management during the inpatient enteral feeding of stroke patients with diabetes; June 2012, JBDS 05 Self-management of diabetes in hospital; March 2012, JBDS 04 Management of adults with diabetes undergoing surgery and elective procedures: improving standards; April 2011, JBDS 03 The Management of Diabetic Ketoacidosis in Adults; revised September 2013, JBDS 02 The hospital management of hypoglycaemia in adults with diabetes mellitus; revised September 2013, JBDS 01 These documents are available to download from: ABCD website: www.diabetologists-abcd.org.uk/JBDS/JBDS.htm Diabetes UK website: www.diabetes.org.uk Contents Page Foreword 4 Authorship and acknowledgments 5-6 Introduction 7 Steroids - mechanism of action 8 Steroid therapy – impact on blood glucose 9 Glucose targets 10 Glucose monitoring 11 Diabetes treatment options 12-13 Treatment of steroid induced hyperglycaemia 14-15 Hospital discharge 16-17 Steroid treatment in pregnancy 18 Steroid treatment in end of life 19 Audit standards 20 Controversial areas 21 References 22 Appendix 1 – Algorithm to show treatment of steroid 23 induced diabetes Appendix 2 – Algorithm to show management of patients 24 with diabetes on once daily steroids Appendix 3 – End of life steroid management 25 Appendix 4 – Patient letter – Glucose monitoring and 26 steroid use 3 Foreword This is the latest in the series of Joint British Diabetes Societies for Inpatient Care (JBDS-IP) guidelines, and focuses on steroid induced hyperglycaemia and steroid induced diabetes.
    [Show full text]
  • Prevention of Diabetic Foot Complications
    Singapore Med J 2018; 59(6): 291-294 Commentary https://doi.org/10.11622/smedj.2018069 Prevention of diabetic foot complications Aziz Nather1, FRCSE, Shuo Cao1, Jamie Li Wen Chen1, An Yee Low1 ABSTRACT This paper discussed the importance of prevention of diabetic foot ulcers and our institution’s protocol for prevention, reviewing the existing evidence in the literature regarding the effectiveness of the preventive approach. Diabetes mellitus is the second most significant cause of disease in Singapore after ischaemic heart disease. National University Hospital, Singapore, adopts a two-pronged strategy for the management of diabetic foot ulcers. The most important strategy is prevention, and education is key. Education should mainly be directed at patients and caregivers, but also professionals (general practitioners, allied health professionals and nurses) so that they can effectively educate patients and caregivers. Patient education includes care of diabetes mellitus, care of the foot and use of appropriate footwear. Patients also tend to have poor foot hygiene. Annual foot screening for diagnosed diabetics plays an important role. However, prolonged and sustained government intervention is necessary to provide education and screening on a national scale. Keywords: annual foot screening, care of diabetes, care of foot and choice of footwear, education, prevention of diabetic foot wounds INTRODUCTION screening are required to prevent diabetic foot problems, with the Diabetes mellitus is on the rise in Singapore. It is now the second help of government intervention to run education and screening most significant cause of ill-health and disease in Singapore after programmes on a national scale. Our institution, the National ischaemic heart disease, affecting one in nine Singaporeans.
    [Show full text]
  • UNIVERSITY of CALIFORNIA, IRVINE Combinatorial Regulation By
    UNIVERSITY OF CALIFORNIA, IRVINE Combinatorial regulation by maternal transcription factors during activation of the endoderm gene regulatory network DISSERTATION submitted in partial satisfaction of the requirements for the degree of DOCTOR OF PHILOSOPHY in Biological Sciences by Kitt D. Paraiso Dissertation Committee: Professor Ken W.Y. Cho, Chair Associate Professor Olivier Cinquin Professor Thomas Schilling 2018 Chapter 4 © 2017 Elsevier Ltd. © 2018 Kitt D. Paraiso DEDICATION To the incredibly intelligent and talented people, who in one way or another, helped complete this thesis. ii TABLE OF CONTENTS Page LIST OF FIGURES vii LIST OF TABLES ix LIST OF ABBREVIATIONS X ACKNOWLEDGEMENTS xi CURRICULUM VITAE xii ABSTRACT OF THE DISSERTATION xiv CHAPTER 1: Maternal transcription factors during early endoderm formation in 1 Xenopus Transcription factors co-regulate in a cell type-specific manner 2 Otx1 is expressed in a variety of cell lineages 4 Maternal otx1 in the endodermal conteXt 5 Establishment of enhancers by maternal transcription factors 9 Uncovering the endodermal gene regulatory network 12 Zygotic genome activation and temporal control of gene eXpression 14 The role of maternal transcription factors in early development 18 References 19 CHAPTER 2: Assembly of maternal transcription factors initiates the emergence 26 of tissue-specific zygotic cis-regulatory regions Introduction 28 Identification of maternal vegetally-localized transcription factors 31 Vegt and OtX1 combinatorially regulate the endodermal 33 transcriptome iii
    [Show full text]
  • Acquired Evolution of Mitochondrial Metabolism Regulated by HNF1B in Ovarian Clear Cell Carcinoma
    cancers Review Acquired Evolution of Mitochondrial Metabolism Regulated by HNF1B in Ovarian Clear Cell Carcinoma Ken Yamaguchi 1,*, Sachiko Kitamura 1, Yoko Furutake 1 , Ryusuke Murakami 1,2 , Koji Yamanoi 1, Mana Taki 1, Masayo Ukita 1, Junzo Hamanishi 1 and Masaki Mandai 1 1 Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan; [email protected] (S.K.); [email protected] (Y.F.); [email protected] (R.M.); [email protected] (K.Y.); [email protected] (M.T.); [email protected] (M.U.); [email protected] (J.H.); [email protected] (M.M.) 2 Department of Gynecology, Shiga General Hospital, Moriyama, Shiga 524-8524, Japan * Correspondence: [email protected]; Tel.: +81-75-751-3269 Simple Summary: Ovarian clear cell carcinoma (CCC) exhibits unique characteristics, including slow growth, glycogen accumulation in the cytoplasm, and poor prognosis for stress resistance. Several molecular targeting agents have failed to treat ovarian CCC. Recent reports have identified metabolic alterations through HNF1B, which is highly expressed in ovarian CCC. The Warburg effect, GSH synthesis, and mitochondrial regulation occur in CCC. The metabolic behaviors of ovarian CCC resemble the evolution of life to survive in stressful environments. Understanding the fundamental biology of ovarian CCC might help in the development of novel therapeutic strategies. Citation: Yamaguchi, K.; Kitamura, Abstract: Clear cell carcinoma (CCC) of the ovary exhibits a unique morphology and clinically S.; Furutake, Y.; Murakami, R.; malignant behavior.
    [Show full text]
  • Diabetes Medication Reference for Clinicians This Table Provides Clinicians a Brief Overview of Examples of Medications Used to Treat Diabetes
    Diabetes Medication Reference for Clinicians This table provides clinicians a brief overview of examples of medications used to treat diabetes. This is not a complete list and is not intended to be used as a sole reference. Nursing responsibilities with ALL diabetes medications: Emphasize importance of self-monitoring of blood glucose (SMBG); teach to be aware of signs/symptoms of allergic reactions; teach to be aware of possible side effects and contraindications; and monitor A1C levels. Oral Medication Action Possible Side-effects Contraindications Nursing Responsibilities Biguanide • Lowers glucose levels • Anorexia, nausea, • Renal disease Patient education: • metformin by decreasing the vomiting, diarrhea - • Liver failure or • Take with food (Glucophage, amount of glucose usually occurs during alcohol abuse (can • Keep appointments Glucophage XR, produced by the liver initiation of the drug result in lactic for regular kidney Glumetza, Fortamet, • Increases glucose • Vitamin B-12 acidosis) function lab tests Riomet) uptake in muscle deficiency • Temporarily held on • Avoid alcohol • Multiple combinations cells • Lactic acidosis day of procedures • Report abnormal with other classes • Improves (severe but rare) with dye and glucose levels • First line therapy for hyperglycemia & • Should not cause withheld 48 hours • Report s/s lactic type 2 diabetes; hypertriglyceridemia hypoglycemia as after the procedure; acidosis (weakness, current in obese patients monotherapy restart after drowsiness, malaise) recommendation is to with diabetes; may confirmation of renal start upon diagnosis promote weight loss function This material was prepared by Quality Insights, the Medicare Quality Innovation Network-Quality Improvement Organization supporting the Home Health Quality Improvement National 1 Campaign, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S.
    [Show full text]
  • Type 2 Diabetes Guidelines
    Type 2 Diabetes Guidelines Version 4 Revised September 2012 for the DECENT Network Diabetes Education Care & Evaluation North of the Tees Covering the Stockton on Tees, Hartlepool and Easington areas Type 2 Diabetes Guidelines for the DECENT Network 1 NICE Diabetes in adults Quality Standards of Care 2011 1. People with diabetes and/or their carers receive a structured educational programme that fulfils the nationally agreed criteria from the time of diagnosis, with annual review and access to ongoing education. 2. People with diabetes receive personalised advice on nutrition and physical activity from an appropriately trained healthcare professional or as part of a structured educational programme. 3. People with diabetes participate in annual care planning which leads to documented agreed goals and an action plan. 4. People with diabetes agree with their healthcare professional a documented personalised HbA1c target, usually between 48 mmol/mol and 58 mmol/mol, and receive an ongoing review of treatment to minimise hypoglycaemia. 5. People with diabetes agree with their healthcare professional to start, review and stop medications to lower blood glucose, blood pressure and blood lipids in accordance with NICE guidance. 6. Trained healthcare professionals initiate and manage therapy with insulin within a structured programme that includes dose titration by the person with diabetes. 7. Women of childbearing age with diabetes are regularly informed of the benefits of preconception glycaemic control and of any risks, including medication that may harm an unborn child. Women with diabetes planning a pregnancy are offered preconception care and those not planning a pregnancy are offered advice on contraception.
    [Show full text]